Adagio Medical Holdings (ADGM) Cash & Equivalents (2023 - 2026)

Adagio Medical Holdings (ADGM) has 4 years of Cash & Equivalents data on file, last reported at $12.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 0.77% year-over-year to $12.9 million; the trailing twelve-month figure through Mar 2026 stood at $12.9 million (down 0.77% YoY), and the FY2025 full-year result was $17.1 million, down 16.91% from the prior year.
• Cash & Equivalents eased to $12.9 million in Q1 2026, from $17.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $28.3 million in Q3 2024 to a low of $1.4 million in Q4 2023.
• A 4-year average of $13.3 million and a median of $13.0 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 1388.5% in 2024 and tumbled 83.46% in 2025, its largest moves.
• Tracing ADGM's Cash & Equivalents over 4 years: stood at $1.4 million in 2023, then surged by 1388.5% to $20.6 million in 2024, then fell by 16.91% to $17.1 million in 2025, then slipped by 24.58% to $12.9 million in 2026.
• Business Quant data shows ADGM's Cash & Equivalents at $12.9 million in Q1 2026, $17.1 million in Q4 2025, and $4.7 million in Q3 2025.